Prospective multicenter observation study of anti-PD-1/PD-L1 antibody re-treatment who previously treated with anti-PD-1/PD-L1 antibody plus chemotherapy
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000038413
- Lead Sponsor
- orth Japan Lung Cancer Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 70
Not provided
1) Active double cancer 2) Patients with a history of severe immune-related adverse events associated with anti-PD-1/PD-L1 antibody 3) Patients with active autoimmune disease 4) Patients with infectious disease requiring systemic treatment 5) Radiographically confirmed interstitial pneumonitis or pulmonary fibrosis 6) Patients with significant complications 7) Patiens who are undergoing systemic administration of steroid greater than 10mg daily of prednisone 8) History or severe drug allergies 9) Pregnant females, possibly pregnant females, females wishing to become pregnant, females of breastfeeding and males wishing to their partner's pregnant 10) Physician concludes that the patient's participation is inappropriate
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall Response Rate
- Secondary Outcome Measures
Name Time Method